Uğur Şahin, BioNTech CEO (Kay Nietfeld/picture-alliance/dpa/AP Images)

As BioN­Tech pre­dicts a drop in its moth­er lode of Covid sales, ex­ecs hint at com­ing M&A deals

BioN­Tech’s Covid-19 vac­cine took cen­ter stage at the com­pa­ny’s Q1 call with in­vestors on Mon­day — and though ex­ecs saw sales triple last quar­ter, they’re al­so think­ing about what comes next as the pan­dem­ic’s course re­mains un­cer­tain.

That leaves the door open for some po­ten­tial M&A ac­tion, ac­cord­ing to CFO Jens Hol­stein, though he de­clined to get in­to the de­tails.

“The main fo­cus of our in­vest­ments re­mains to in­vest in our re­search and de­vel­op­ment ac­tiv­i­ties,” Hol­stein said on the call. “We have of course looked, and con­tin­u­ous­ly look, in­to ad­di­tions in terms of trans­ac­tions that we can make, col­lab­o­ra­tions, all kinds of things … but we can’t give you clos­er guid­ance on where and when we will in­vest.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.